Health Catalyst Reports Preliminary 2025 Results Exceeding Revenue and Client Targets, Outlines 2026 Strategic Focus
HCAT sits 22% above its 52-week low of $2.015.
Summary
Health Catalyst, Inc. announced preliminary unaudited 2025 financial results, reporting revenue slightly above guidance and new platform clients exceeding targets, alongside strategic updates for 2026.
Key Events · Earnings and Guidance · HCAT
-
Preliminary 2025 Financial Performance
Health Catalyst reported preliminary unaudited 2025 results, with total revenue slightly exceeding guidance of ~$310M and Adjusted EBITDA in line with ~$41M guidance.
-
Strong Client Acquisition
The company added 32 net new Platform Clients, surpassing its target of 30, with average annual recurring revenue (ARR) and non-recurring revenue near the midpoint of the $300k to $700k range.
-
Strategic Focus for 2026
Health Catalyst plans to sharpen its strategic focus on core offerings, rebalance investments, and continue advancing its client-centric Ignite migration efforts.
-
Operational and Growth Initiatives
Plans include increased investment in India resourcing and AI utilization in 2026, with an expectation of higher overall bookings than in 2025.
Analysis · HCAT · Technology
This 8-K filing provides investors with an early look at Health Catalyst's 2025 performance, indicating stronger-than-expected revenue and client acquisition. The company's strategic focus on core offerings, client-centric migration, and investment in AI and India resourcing for 2026 suggests a proactive approach to enhancing value and optimizing costs. While these results are preliminary and subject to audit, the positive trends and forward-looking commentary offer a favorable outlook for the company's operational and financial trajectory. Investors should monitor the upcoming full earnings call for more detailed 2026 guidance and audited results.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $2.46 on NASDAQ in the Technology sector, with a market capitalization of approximately $174M. The 52-week trading range was $2.02 to $7.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.